Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2016-11-709873 http://scihub22266oqcxt.onion/10.1182/blood-2016-11-709873 C5445568!5445568 !28416511     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28416511 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28416511 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Blood 2017 ; 129 (21 ): 2864-2872 Nephropedia Template TP {{tp|p=28416511 |t=2017. Heparin-induced thrombocytopenia |pdf=|usr=}}{{28416511 }} gab.com Text Heparin-induced thrombocytopenia JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=28416511 #FOAvip Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic antibodies to PF4/heparin bind and activate cellular Fc?RIIA on platelets and monocytes to propagate a hypercoagulable state culminating in life-threatening thrombosis. It is now recognized that anti-PF4/heparin antibodies develop commonly after heparin exposure, but only a subset of sensitized patients progress to life-threatening complications of thrombocytopenia and thrombosis. Recent scientific developments have clarified mechanisms underlying PF4/heparin immunogenicity, disease susceptibility, and clinical manifestations of disease. Insights from clinical and laboratory findings have also been recently harnessed for disease prevention. This review will summarize our current understanding of HIT by reviewing pathogenesis, essential clinical and laboratory features, and management. Twit Text FOAVip Heparin-induced thrombocytopenia ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=28416511 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28416511 #FOAvip English Wikipedia <ref>{{Cite pmid|28416511 }}</ref> Heparin-induced thrombocytopenia #MMPMID28416511 Arepally GM Blood 2017[May]; 129 (21 ): 2864-2872 PMID28416511 show ga Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic antibodies to PF4/heparin bind and activate cellular Fc?RIIA on platelets and monocytes to propagate a hypercoagulable state culminating in life-threatening thrombosis. It is now recognized that anti-PF4/heparin antibodies develop commonly after heparin exposure, but only a subset of sensitized patients progress to life-threatening complications of thrombocytopenia and thrombosis. Recent scientific developments have clarified mechanisms underlying PF4/heparin immunogenicity, disease susceptibility, and clinical manifestations of disease. Insights from clinical and laboratory findings have also been recently harnessed for disease prevention. This review will summarize our current understanding of HIT by reviewing pathogenesis, essential clinical and laboratory features, and management. |*Autoantibodies/blood/immunology [MESH] |*Platelet Factor 4/antagonists & inhibitors/blood/immunology [MESH] |*Receptors, IgG/blood/immunology [MESH] |*Thrombocytopenia/blood/chemically induced/immunology/prevention & control [MESH] |Heparin/*adverse effects [MESH] |Humans [MESH]Heparin-induced thrombocytopenia (epmc).pdf DeepDyve Pubget Overpricing